2. Search Result
Search Result
Results for "

atherogenic

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

4

Peptides

1

Inhibitory Antibodies

11

Natural
Products

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0292
    Oleuropein
    Maximum Cited Publications
    9 Publications Verification

    		 Cytochrome P450 PPAR Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity . Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase .
    Oleuropein
  • HY-19522
    Seladelpar
    1 Publications Verification

    MBX-8025; RWJ-800025

    		 PPAR Metabolic Disease
    Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .
    Seladelpar
  • HY-113342
    7-Ketocholesterol
    5 Publications Verification

    		 Endogenous Metabolite p38 MAPK Cardiovascular Disease Metabolic Disease
    7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis) .
    7-Ketocholesterol
  • HY-113270
    Actinine

    γ-Butyrobetaine; Deoxycarnitine

    		 Endogenous Metabolite Metabolic Disease
    Actinine is a metabolic and pro-atherogenic intermediate with oral activity. Actinine acts as a substrate for the yeaW/X microbial enzyme complex to generate trimethylamine (TMA). Actinine accelerates atherosclerosis development in a gut microbe-dependent manner. Actinine can be used for the research of atherosclerosis .
    Actinine
  • HY-18778
    Obicetrapib

    TA-8995; DEZ-001; AMG-899

    		 CETP Apolipoprotein LPL Receptor LDLR Cardiovascular Disease
    Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib
  • HY-19900
    ITX5061
    3 Publications Verification

    		 p38 MAPK Scavenger Receptor Class B type I (SR-BI） Inflammation/Immunology
    ITX5061 is an orally active type II non-competitive p38 MAPK inhibitor. ITX5061 increases HDL-C levels by inhibiting SR-BI activity. ITX5061 also moderately elevates ApoA-I levels. ITX5061 reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 can be used in the research of atherosclerosis .
    ITX5061
  • HY-N4137
    Tormentic acid
    2 Publications Verification

    		 Others Cardiovascular Disease Inflammation/Immunology
    Tormentic acid, a triterpene isolated from Rosa rugosa, exerts anti-inflammatory, antihyperlipidemic, and anti-atherogenic properties .
    Tormentic acid
  • HY-101448
    TMI-1
    1 Publications Verification

    WAY-171318

    		 MMP Apoptosis Interleukin Related TNF Receptor Caspase Infection Neurological Disease Inflammation/Immunology Cancer
    TMI-1 (WAY-171318) inhibits TNF converting enzyme (TACE) (IC50 of 8.4 nM), ADAM-TS-4, ADAM-17 and various MMPs with oral activity. TMI-1 significantly suppresses the secretion of TNF-α , alleviating collagen-induced arthritis in mice. TMI-1 inhibits cancer cell proliferation, induces apoptosis through a caspase-dependent pathway. TMI-1 also reverses TRPV1 upregulation and lowers the levels of inflammatory factors (TNF-α、IL-1β、IL-6) in nerve cells, protecting against paclitaxel-induced neurotoxicity. TMI-1 leads to changes in pro-atherogenic lipoprotein profiles, but does not affect the progression of early lesions .
    TMI-1
  • HY-W015780
    1,4-Dimethoxybenzene

    		Environmental Pollutants Endogenous Metabolite Metabolic Disease
    1,4-Dimethoxybenzene is an endogenous metabolite. 1,4-Dimethoxybenzene has an anti-anxiety effect, increasing atherogenic index (AI) levels in rabbits and inducing sedentary behavior. Sedentary behavior may increase blood cholesterol levels and disrupt blood lipids . 1,4-Dimethoxybenzene considers to be not clastogenic in the in vivo micronucleus test .
    1,4-Dimethoxybenzene
  • HY-126356
    1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine

    		Liposome Cardiovascular Disease
    1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .
    1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
  • HY-N8572
    3',4'-Dimethoxyflavone
    1 Publications Verification

    		 PARP Reactive Oxygen Species (ROS) Aryl Hydrocarbon Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of PARP and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects .
    3',4'-Dimethoxyflavone
  • HY-153497A
    Vupanorsen sodium

    IONIS ANGPT-L3Rx sodium; ISIS 703802 sodium

    		 ANGPTL Metabolic Disease
    Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.
    Vupanorsen sodium
  • HY-N0292R
    Oleuropein (Standard)

    		Cytochrome P450 Reference Standards PPAR Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Oleuropein (Standard) is the analytical standard of Oleuropein. This product is intended for research and analytical applications. Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity . Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase .
    Oleuropein (Standard)
  • HY-19522C
    Seladelpar (lysine dihydrate)
    1 Publications Verification

    MBX-8025 (lysine dihydrate); RWJ-800025 (lysine dihydrate)

    		 PPAR Metabolic Disease
    Seladelpar (MBX-8025) Lysine dihydrate is the Lysine dihydrate salt form of Seladelpar (HY-19522). Seladelpar Lysine dihydrate is an orally active agonist for potent PPAR-δ, with EC50 of 2 nM. Seladelpar Lysine dihydrate shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar Lysine dihydrate can be used for the study of primary biliary cholangitis. Seladelpar Lysine dihydrate normalizes hyperglycemia, hyperinsulinemia, glucose, serum lipids and cholesterol levels, ameliorates the nonalcoholic steatohepatitis in mouse model .
    Seladelpar (lysine dihydrate)
  • HY-134154
    PAz-PC

    PAzePC; Azelaoyl PC; 1-Palmitoyl-2-Azelaoyl PC

    		 Endogenous Metabolite Metabolic Disease
    Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. Many of these substances were isolated and purified from oxLDL and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. PAz-PC (Azelaoyl PC) is one of the predominant oxLDL species and may be one of the important structural determinants of oxLDL.
    PAz-PC
  • HY-153497
    Vupanorsen

    IONIS ANGPT-L3Rx; ISIS 703802

    		 ANGPTL Metabolic Disease
    Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.
    Vupanorsen
  • HY-19522B
    Seladelpar (lysine)
    1 Publications Verification

    MBX-8025 (lysine); RWJ-800025 (lysine)

    		 PPAR Metabolic Disease
    Seladelpar (MBX-8025) lysine is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar lysine shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar lysine can be used for the study of primary biliary cholangitis .
    Seladelpar (lysine)
  • HY-19522R
    Seladelpar (Standard)

    MBX-8025 (Standard); RWJ-800025 (Standard)

    		 PPAR Reference Standards Metabolic Disease
    Seladelpar (Standard) is the analytical standard of Seladelpar. This product is intended for research and analytical applications. Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .
    Seladelpar (Standard)
  • HY-N8572R
    3',4'-Dimethoxyflavone (Standard)

    		Reference Standards PARP Reactive Oxygen Species (ROS) Aryl Hydrocarbon Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of PARP and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects .
    3',4'-Dimethoxyflavone (Standard)
  • HY-120309
    BMY 42393

    		Prostaglandin Receptor Cardiovascular Disease
    BMY 42393 is an orally active prostacyclin agonist which suppresses monocyte-macrophage atherogenic activity and cytokine production. BMY 42393 can be used for atherosclerosis research .
    BMY 42393
  • HY-120943
    K-111

    BM 17.0744

    		 PPAR Metabolic Disease
    K-111 (BM-170744) is an oral active PPAR alpha agonist. K-111 show efficacy in improving insulin resistance, reducing body weight, and ameliorating atherogenic dyslipidemia. K-111 can be used for study of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome .
    K-111
  • HY-N4137R
    Tormentic acid (Standard)

    		Reference Standards Others Cardiovascular Disease Inflammation/Immunology
    Tormentic acid (Standard) is the analytical standard of Tormentic acid. This product is intended for research and analytical applications. Tormentic acid, a triterpene isolated from Rosa rugosa, exerts anti-inflammatory, antihyperlipidemic, and anti-atherogenic properties .
    Tormentic acid (Standard)
  • HY-121542
    PPARδ agonist 10

    		PPAR Metabolic Disease
    PPARδ agonist 10 (compound 7) is an orally active, selective, and partial agonist of PPARδ, with EC50 values of 0.053 μM and 0.30 µM for hPPARδ(LBD)-GAL4 and mPPARδ, respectively. PPARδ agonist 10 is a partial PPARδ agonist in transactivation assay but a full agonist on free fatty acids (FFA) oxidation in muscle cells both in vitro and in vivo. PPARδ agonist 10 can be used for dyslipidemia research .
    PPARδ agonist 10
  • HY-P5169
    LVGRQLEEFL (mouse)

    		Apolipoprotein Amino Acid Derivatives Inflammation/Immunology
    LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
    LVGRQLEEFL (mouse)
  • HY-P5169A
    LVGRQLEEFL (mouse) TFA

    		Apolipoprotein Amino Acid Derivatives Inflammation/Immunology
    LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
    LVGRQLEEFL (mouse) TFA
  • HY-113342R
    7-Ketocholesterol (Standard)

    		Endogenous Metabolite p38 MAPK Reference Standards Cardiovascular Disease Metabolic Disease
    7-Ketocholesterol (Standard) is the analytical standard of 7-Ketocholesterol. This product is intended for research and analytical applications. 7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis) .
    7-Ketocholesterol (Standard)
  • HY-P992470
    STT-5058

    ARGX-116; NN5058

    		 Apolipoprotein Cardiovascular Disease Metabolic Disease
    STT-5058 (ARGX-116; NN5058) is a human monoclonal antibody targeting ApoC3 and belongs to the class of ApoC3 inhibitors. STT-5058 exhibits pH-dependent circulation properties and binds to a unique epitope on ApoC3. STT-5058 reduces triglyceride levels and accelerates the clearance of atherogenic remnant lipoproteins containing ApoC3. STT-5058 can be used in research related to hypertriglyceridemia, dyslipidemia and cardiovascular diseases .
    STT-5058
  • HY-18778B
    Obicetrapib potassium

    TA-8995 potassium; DEZ-001 potassium; AMG-899 potassium

    		 Apolipoprotein CETP LPL Receptor LDLR Metabolic Disease
    Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib potassium
  • HY-18778A
    Obicetrapib sodium

    TA-8995 sodium; DEZ-001 sodium; AMG-899 sodium

    		 Apolipoprotein CETP LPL Receptor LDLR Cardiovascular Disease
    Obicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib sodium
  • HY-122068
    ITX5061 free base

    		p38 MAPK Scavenger Receptor Class B type I (SR-BI） Inflammation/Immunology
    ITX5061 free base is an orally active type II non-competitive p38 MAPK inhibitor. ITX5061 free base increases HDL-C levels by inhibiting SR-BI activity. ITX5061 free base also moderately elevates ApoA-I levels. ITX5061 free base reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 free base can be used in the research of atherosclerosis .
    ITX5061 free base
  • HY-W1126955
    Enlicitide (decanoate)

    MK-0616 (decanoate)

    		 PCSK9 Metabolic Disease Inflammation/Immunology
    Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease .
    Enlicitide (decanoate)
  • HY-182014
    TLC-2716

    		LXR Cardiovascular Disease Metabolic Disease
    TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders .
    TLC-2716
  • HY-101448R
    TMI-1 (Standard)

    WAY-171318 (Standard)

    		 MMP Reference Standards Apoptosis Interleukin Related TNF Receptor Caspase Infection Neurological Disease Inflammation/Immunology Cancer
    TMI-1 (Standard) is the analytical standard of TMI-1 (HY-101448). This product is intended for research and analytical applications. TMI-1 (WAY-171318) inhibits TNF converting enzyme (TACE) (IC50 of 8.4 nM), ADAM-TS-4, ADAM-17 and various MMPs with oral activity. TMI-1 significantly suppresses the secretion of TNF-α , alleviating collagen-induced arthritis in mice. TMI-1 inhibits cancer cell proliferation, induces apoptosis through a caspase-dependent pathway. TMI-1 also reverses TRPV1 upregulation and lowers the levels of inflammatory factors (TNF-α、IL-1β、IL-6) in nerve cells, protecting against paclitaxel-induced neurotoxicity. TMI-1 leads to changes in pro-atherogenic lipoprotein profiles, but does not affect the progression of early lesions .
    TMI-1 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: